248 related articles for article (PubMed ID: 15181145)
21. Initial investigations of 99mTc-labeled morpholinos for radiopharmaceutical applications.
Mang'era KO; Liu G; Yi W; Zhang Y; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
Eur J Nucl Med; 2001 Nov; 28(11):1682-9. PubMed ID: 11702111
[TBL] [Abstract][Full Text] [Related]
22. Optical pretargeting of tumor with fluorescent MORF oligomers.
He J; Rusckowski M; Wang Y; Dou S; Liu X; Zhang S; Liu G; Hnatowich DJ
Mol Imaging Biol; 2007; 9(1):17-23. PubMed ID: 17171474
[TBL] [Abstract][Full Text] [Related]
23. Preparation of (111)In-DTPA morpholino oligomer for low abdominal accumulation.
Liu G; Dou S; Rusckowski M; Greiner D; Hnatowich D
Appl Radiat Isot; 2010 Sep; 68(9):1709-14. PubMed ID: 20359901
[TBL] [Abstract][Full Text] [Related]
24. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
Griffiths GL; Chang CH; McBride WJ; Rossi EA; Sheerin A; Tejada GR; Karacay H; Sharkey RM; Horak ID; Hansen HJ; Goldenberg DM
J Nucl Med; 2004 Jan; 45(1):30-9. PubMed ID: 14734668
[TBL] [Abstract][Full Text] [Related]
25. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector.
Liu G; Dou S; Rusckowski M; Hnatowich DJ
Mol Cancer Ther; 2008 May; 7(5):1025-32. PubMed ID: 18483292
[TBL] [Abstract][Full Text] [Related]
26. Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.
Liu G; Cheng D; Dou S; Chen X; Liang M; Pretorius PH; Rusckowski M; Hnatowich DJ
Mol Imaging Biol; 2009; 11(5):303-7. PubMed ID: 19326173
[TBL] [Abstract][Full Text] [Related]
27. A novel pretargeting method for measuring antibody internalization in tumor cells.
Liu G; Dou S; Yin D; Squires S; Liu X; Wang Y; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2007 Feb; 22(1):33-9. PubMed ID: 17461727
[TBL] [Abstract][Full Text] [Related]
28. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.
Liu G; Dou S; Chen X; Chen L; Liu X; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2010 Dec; 25(6):757-62. PubMed ID: 21204772
[TBL] [Abstract][Full Text] [Related]
29. A comparison of in vitro and in vivo stability in mice of two morpholino duplexes differing in chain length.
He J; Liu G; Zhang S; Vanderheyden JL; Liu N; Liu C; Zhang Y; Gupta S; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2003; 14(5):1018-23. PubMed ID: 13129406
[TBL] [Abstract][Full Text] [Related]
30. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
31. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.
Liu G; Dou S; He J; Yin D; Gupta S; Zhang S; Wang Y; Rusckowski M; Hnatowich DJ
Appl Radiat Isot; 2006 Sep; 64(9):971-8. PubMed ID: 16730997
[TBL] [Abstract][Full Text] [Related]
32. Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.
Dou S; Wang Y; Barton B; Chen L; Rusckowski M; Shultz LD; Greiner DL; Liu G
Nucl Med Biol; 2014 Jan; 41(1):127-31. PubMed ID: 24210286
[TBL] [Abstract][Full Text] [Related]
33. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
[TBL] [Abstract][Full Text] [Related]
34. Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model.
Liu G; Dou S; Cheng D; Leif J; Rusckowski M; Streeter PR; Shultz LD; Hnatowich DJ; Greiner DL
Mol Pharm; 2011 Jun; 8(3):767-73. PubMed ID: 21361360
[TBL] [Abstract][Full Text] [Related]
35. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.
Liu G; Dou S; Liu Y; Wang Y; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2011 Dec; 22(12):2539-45. PubMed ID: 21985267
[TBL] [Abstract][Full Text] [Related]
36. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
37. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
Nock BA; Maina T; Béhé M; Nikolopoulou A; Gotthardt M; Schmitt JS; Behr TM; Mäcke HR
J Nucl Med; 2005 Oct; 46(10):1727-36. PubMed ID: 16204724
[TBL] [Abstract][Full Text] [Related]
38. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
39. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
[TBL] [Abstract][Full Text] [Related]
40. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor.
Blankenberg FG; Mandl S; Cao YA; O'Connell-Rodwell C; Contag C; Mari C; Gaynutdinov TI; Vanderheyden JL; Backer MV; Backer JM
J Nucl Med; 2004 Aug; 45(8):1373-80. PubMed ID: 15299064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
